PHVS
Pharvaris N.V.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+1/100
Last price
32.00
▲ 0.88 (2.83%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
30.97
Prev close
31.12
Day high
32.08
Day low
30.58
Volume
104.08K
Market cap
$2.25B
P/E (TTM)
—
52W range
20.65 – 43.25
Day trading desk
Gap from prior close
-0.48%
Prior close 31.12
VWAP
31.74
+0.83% from price
Relative volume
0.13×
Quiet session
Session range
5.12%
30.58 – 32.14
Position in range
91%
Near session high
ATR (14D)
1.42
4.44% of price
Prior day high
31.27
PDH
Prior day low
30.15
PDL
Bid / ask spread
—
Quote not published
Session volume
96.43K
Avg 740.93K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.88%
-0.7%
1M
-15.43%
-16.6%
3M
-11.01%
-14.1%
6M
+16.11%
+1.5%
YTD
+15.32%
+1.7%
1Y
+37.63%
+22.3%
3Y
+72.97%
-8.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PHVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-120.52K
Net selling
Buy transactions
26
821.70K shares
Sell transactions
42
942.22K shares
Net transactions
+68
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
4.31M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 26 | SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS Director |
SELL | 800 | $28.95K | Direct |
| Sep 22, 26 | SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS Director |
CONVERSION | 800 | $16.00K | Direct |
| Sep 22, 26 | LU PENG President |
CONVERSION | 45.31K | $117.35K | Direct |
| Sep 21, 26 | NASSIF DAVID W Chief Financial Officer |
STOCK | 500 | $0 | Direct |
| Sep 21, 26 | NASSIF DAVID W Chief Financial Officer |
SELL | 6.00K | $218.80K | Direct |
| Sep 17, 26 | LESAGE ANNE SIMONNE J PH.D. Officer |
SELL | 20.00K | $765.47K | Indirect |
| Sep 17, 26 | SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS Director |
SELL | 200.00K | $7.00M | Direct |
| Sep 17, 26 | GLASSMAN ROBERT R. Director |
SELL | 14.49K | $558.81K | Direct |
| Sep 17, 26 | GLASSMAN ROBERT R. Director |
CONVERSION | 14.49K | $262.90K | Direct |
| Sep 17, 26 | MODIG BERNDT B.A.E Chief Executive Officer |
CONVERSION | 300.00K | $10.50M | Indirect |
| Sep 17, 26 | BJORK ELISABETH Director |
SELL | 52.50K | $1.99M | Direct |
| Sep 17, 26 | BJORK ELISABETH Director |
CONVERSION | 52.50K | $821.10K | Direct |
| Sep 17, 26 | LU PENG President |
SELL | 100.00K | $3.50M | Direct |
| Sep 17, 26 | LU PENG President |
CONVERSION | 100.00K | $259.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABELE STEFAN |
Chief Operating Officer | 39.07K | Sale |
BJORK ELISABETH |
Director | 15.17K | Sale |
GLASSMAN ROBERT R. |
Director | 10.50K | Sale |
LESAGE ANNE SIMONNE J PH.D. |
Officer | — | Sale |
LU PENG |
President | 110.26K | Conversion of Exercise of derivative security |
MODIG BERNDT B.A.E |
Chief Executive Officer | — | Conversion of Exercise of derivative security |
NASSIF DAVID W |
Chief Financial Officer | 113.80K | Stock Gift |
NIJDAM ANNA |
Officer | 46.27K | Sale |
SCHIKAN JOHANNES GERARDUS CHRISTIAAN PETRUS |
Director | 115.17K | Sale |
SOUVERIJNS WIM PH.D. |
Officer | 39.02K | Sale |
Fundamentals
Market cap$2.25B
Enterprise value$1.87B
Revenue (TTM)—
Gross profit—
EBITDA$-182.17M
Net income$-170.92M
EPS (TTM)$-3.06
Free cash flow$-90.36M
Total cash$318.28M
Total debt$673.73K
Book value / share$4.91
Shares outstanding70.20M
Float44.13M
Short % of float3.09%
Dividend yield0.00%
Beta (5Y)-2.46
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.53
PEG ratio—
Price / sales—
Price / book6.52
EV / revenue—
EV / EBITDA-10.25
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-70.46%
Return on assets-42.32%
Debt / equity0.22
Current ratio11.94
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $124.48M | $98.56M | $65.58M | $57.38M | +26.3% |
| Selling, general & admin | $45.34M | $47.12M | $31.34M | $29.34M | -3.8% |
| Total operating expense | $169.82M | $145.69M | $96.91M | $86.71M | +16.6% |
| Operating income | -$169.82M | -$145.69M | -$96.91M | -$86.71M | -16.6% |
| Net interest income | $6.36M | $5.42M | $204.02K | -$39.25K | +17.3% |
| Pre-tax income | -$173.71M | -$132.40M | -$99.83M | -$75.65M | -31.2% |
| Tax provision | $1.99M | $1.83M | $1.05M | $679.09K | +8.9% |
| Net income | -$175.70M | -$134.22M | -$100.88M | -$76.33M | -30.9% |
| Net income to common | -$175.70M | -$134.22M | -$100.88M | -$76.33M | -30.9% |
| Basic EPS | -2.97 | -2.48 | -2.63 | -2.27 | -19.8% |
| Diluted EPS | -2.97 | -2.48 | -2.63 | -2.27 | -19.8% |
| EBIT | -$169.82M | -$145.69M | -$96.91M | -$86.71M | -16.6% |
| EBITDA | -$169.40M | -$145.42M | -$96.66M | -$86.56M | -16.5% |
| Basic shares | 59.16M | 54.02M | 38.39M | 33.59M | +9.5% |
| Diluted shares | 59.16M | 54.02M | 38.39M | 33.59M | +9.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $291.68M | $280.73M | $391.23M | $161.84M | — | +3.9% |
| Cash & short-term investments | $291.68M | $280.73M | $391.23M | $161.84M | — | +3.9% |
| Accounts receivable | — | — | — | $0 | $8.45K | — |
| Total current assets | $299.17M | $289.42M | $397.85M | $166.85M | — | +3.4% |
| Property, plant & equipment | $1.40M | $1.48M | $455.57K | $626.44K | — | -5.5% |
| Total assets | $301.45M | $291.37M | $398.69M | $167.73M | — | +3.5% |
| Total current liabilities | $29.60M | $22.97M | $14.60M | $18.22M | — | +28.9% |
| Total debt | $776.80K | $861.47K | $238.91K | $436.82K | — | -9.8% |
| Total liabilities | $30.18M | $23.61M | $14.65M | $18.47M | — | +27.8% |
| Retained earnings | -$579.60M | -$402.26M | -$265.92M | -$164.19M | — | -44.1% |
| Shareholder equity | $271.27M | $267.76M | $384.05M | $149.26M | — | +1.3% |
| Working capital | $269.56M | $266.44M | $383.25M | $148.62M | — | +1.2% |
| Net tangible assets | $271.27M | $267.76M | $384.05M | $149.26M | — | +1.3% |
| Shares issued | 65.21M | 54.38M | 52.29M | 33.82M | — | +19.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$173.71M | -$132.40M | -$99.83M | -$75.65M | -31.2% |
| Depreciation & amortisation | $418.35K | $269.56K | $257.55K | $152.94K | +55.2% |
| Stock-based compensation | $19.05M | $16.21M | $10.66M | $11.35M | +17.5% |
| Change in working capital | $7.62M | $5.89M | -$5.86M | $8.38M | +29.4% |
| Operating cash flow | -$137.07M | -$120.13M | -$93.05M | -$67.16M | -14.1% |
| Capital expenditure | -$164.62K | -$538.09K | -$89.98K | -$124.30K | +69.4% |
| Investing cash flow | -$164.62K | -$538.09K | -$89.98K | -$124.30K | +69.4% |
| Financing cash flow | $160.61M | $2.68M | $325.39M | $8.65M | +5,900.5% |
| Free cash flow | -$137.24M | -$120.67M | -$93.14M | -$67.29M | -13.7% |
| End cash position | $291.68M | $280.73M | $391.23M | $161.84M | +3.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $35.00M | $30.16M | $34.14M | $29.81M | $29.61M | — | +16.0% |
| Selling, general & admin | $15.79M | $14.11M | $13.46M | $9.85M | $10.77M | — | +11.9% |
| Total operating expense | $50.79M | $44.27M | $47.60M | $39.66M | $40.37M | — | +14.7% |
| Operating income | -$50.79M | -$44.27M | -$47.60M | -$39.66M | -$40.37M | — | -14.7% |
| Net interest income | $1.91M | $5.34M | $2.13M | $2.10M | $962.41K | — | -64.3% |
| Pre-tax income | -$47.24M | -$38.93M | -$45.08M | -$37.32M | -$45.28M | — | -21.4% |
| Tax provision | $602.20K | $273.11K | $1.66M | -$181.47K | $202.78K | — | +120.5% |
| Net income | -$47.84M | -$39.20M | -$46.74M | -$37.14M | -$45.48M | — | -22.0% |
| Net income to common | -$47.84M | -$39.20M | -$46.74M | -$37.14M | -$45.48M | — | -22.0% |
| Basic EPS | -0.70 | -0.60 | — | -0.60 | -0.83 | -0.85 | -16.8% |
| Diluted EPS | -0.70 | -0.60 | — | -0.60 | -0.83 | -0.85 | -16.8% |
| EBIT | -$50.79M | -$44.27M | -$47.60M | -$39.66M | -$40.37M | — | -14.7% |
| EBITDA | -$50.61M | -$44.17M | -$47.49M | -$39.56M | -$40.27M | — | -14.6% |
| Basic shares | 68.07M | 65.42M | — | 62.26M | 54.69M | 54.49M | +4.0% |
| Diluted shares | 68.07M | 65.42M | — | 62.26M | 54.69M | 54.49M | +4.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $318.28M | $246.96M | $291.68M | $329.29M | $199.57M | +28.9% |
| Cash & short-term investments | $318.28M | $246.96M | $291.68M | $329.29M | $199.57M | +28.9% |
| Total current assets | $326.88M | $257.68M | $299.17M | $337.19M | $208.17M | +26.9% |
| Property, plant & equipment | $1.21M | $1.36M | $1.40M | $1.25M | $1.34M | -10.9% |
| Total assets | $328.67M | $259.79M | $301.45M | $338.90M | $209.81M | +26.5% |
| Total current liabilities | $27.38M | $22.92M | $29.60M | $26.21M | $25.00M | +19.4% |
| Total debt | $673.73K | $738.89K | $776.80K | $578.66K | $634.15K | -8.8% |
| Total liabilities | $27.86M | $23.46M | $30.18M | $26.66M | $25.47M | +18.8% |
| Retained earnings | -$668.58M | -$619.54M | -$579.60M | -$532.38M | -$494.94M | -7.9% |
| Shareholder equity | $300.81M | $236.33M | $271.27M | $312.24M | $184.34M | +27.3% |
| Working capital | $299.50M | $234.76M | $269.56M | $310.97M | $183.17M | +27.6% |
| Net tangible assets | $300.81M | $236.33M | $271.27M | $312.24M | $184.34M | +27.3% |
| Shares issued | 69.88M | 65.42M | 65.21M | 64.96M | 54.74M | +6.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$47.24M | -$38.93M | -$45.08M | -$37.32M | -$45.28M | — | -21.4% |
| Depreciation & amortisation | $179.30K | $104.73K | $104.87K | $105.15K | $103.03K | — | +71.2% |
| Stock-based compensation | $6.63M | $4.90M | $4.54M | $4.89M | $5.50M | — | +35.4% |
| Change in working capital | $6.73M | -$10.61M | $4.87M | $1.85M | $3.20M | — | +163.4% |
| Operating cash flow | -$37.80M | -$48.77M | -$37.95M | -$30.67M | -$29.98M | — | +22.5% |
| Capital expenditure | -$26.91K | -$52.10K | -$1.54K | -$18.71K | — | -$161.00K | +48.4% |
| Investing cash flow | -$26.91K | -$52.10K | -$1.54K | -$18.71K | $16.64K | — | +48.4% |
| Financing cash flow | $105.87M | -$61.51K | $271.49K | $160.43M | -$22.90K | — | +172,213.7% |
| Free cash flow | -$37.83M | -$48.82M | -$37.95M | -$30.69M | -$29.96M | — | +22.5% |
| End cash position | $318.28M | $246.96M | $291.68M | $329.29M | $199.57M | — | +28.9% |
Options analytics
Put / call volume
21.12
Put-heavy session
Put / call open interest
1.97
Positioning, not flow
Max pain
40.00
+25.0% from spot
ATM implied vol
61.3%
Nearest strike to spot
Skew (10% OTM)
-103.2%
Calls bid over puts
Call volume
89
Contracts, this expiry
Put volume
1.88K
Contracts, this expiry
Heaviest call OI
50.00
6.20K contracts
Heaviest put OI
17.50
7.25K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.65 | -0.70 | -7.1% |
| Mar 2026 | -0.71 | — | — |
| Dec 2025 | -0.62 | -0.71 | -15.4% |
| Sep 2025 | -0.67 | -0.60 | +10.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.72 | 11 | $0 | 0.0% |
| Next quarter | -0.77 | 11 | $0 | 0.0% |
| Current year | -2.77 | 13 | $0 | 0.0% |
| Next year | -2.71 | 12 | $32.22M | 0.0% |
Analyst targets & ownership
Mean target$57.18
High target$76.05
Low target$41.00
Implied upside78.70%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders6.14%
Held by institutions93.23%
Institutions holding165
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
31.62
+1.21% from price
SMA 20
34.24
-6.55% from price
SMA 50
34.86
-8.21% from price
SMA 100
33.67
-4.97% from price
SMA 200
30.56
+4.73% from price
EMA 12
32.35
-1.07% from price
EMA 26
33.66
-4.95% from price
EMA 50
34.14
-6.26% from price
RSI (14)
39.6
Neutral
MACD (12,26,9)
-1.32
Hist -0.32
ATR (14)
1.42
4.44% of price
Realised vol 30D
39.3%
Annualised
Bollinger upper
40.06
20, 2σ
Bollinger lower
28.43
20, 2σ
50 / 200 cross
Golden
34.86 vs 30.56
Trend bias
Above 200
+4.73%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.89
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
39.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.5%
Peak to trough
Max drawdown 5Y
-92.8%
Peak to trough
ATR 14
1.42
4.44% of price
Beta (reported)
-2.46
5Y monthly, from filing
Short interest
Shares short
1.78M
Prior 1.78M
Change vs prior
+0.6%
Shorts adding
% of float
3.09%
Normal
% of shares out
2.54%
Against total outstanding
Days to cover
1.7
Liquid
Float
44.13M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 9, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 9, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Sep 9, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Sep 9, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 8, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 13, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-12
Corporate Changes & Voting Matters
6-K · 2026-06-26
Corporate Changes & Voting Matters
6-K · 2026-06-11
Corporate Changes & Voting Matters
6-K · 2026-05-12
Corporate Changes & Voting Matters
6-K · 2026-05-11
Periodic Financial Reports
20-F · 2026-04-02
Corporate Changes & Voting Matters
6-K · 2026-01-12
Corporate Changes & Voting Matters
6-K · 2025-12-03
Headlines
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
GlobeNewswire · 2d ago
Pharvaris Insider Sold Shares Worth $7,000,000, According to a Recent SEC Filing
MT Newswires · 16d ago
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
Simply Wall St. · 18d ago
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
MarketBeat · 19d ago
Pharvaris Insider Sold Shares Worth $1,771,125, According to a Recent SEC Filing
MT Newswires · 20d ago
Pharvaris Insider Sold Shares Worth $1,023,575, According to a Recent SEC Filing
MT Newswires · 21d ago
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Zacks · 22d ago
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Insider Monkey · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.